TIDMFDBK

RNS Number : 0086O

Feedback PLC

27 September 2019

Feedback plc

Statement re share price

Cambridge, 27 September 2019: Feedback plc (AIM: FDBK, "Feedback" or the "Company") notes the movement in the share price today. The Company notes the announcement earlier today by IQ-AI Ltd that Imaging Biometrics, IQ-AI's Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA ("the FDA Clearance"). Stonechecker is a licensee of Feedback's TexRAD(R) software and the Directors believe that the Stonechecker Software uses TexRAD(R) . However, the Company is currently not able to evaluate what level of income, if any, will accrue as a result of the FDA Clearance. In addition, the FDA Clearance does not confer FDA clearance for TexRAD(R) and the Directors are now evaluating the implications of this as part of their ongoing strategic review.

A further announcement will be made in due course.

 
 Enquiries: 
 Feedback plc                                    +44 (0)1954 718072 
  Tom Oakley, CEO                                 IR@fbk.com 
  Lindsay Melvin, CFO 
 Allenby Capital Limited (Nominated Adviser) 
  David Worlidge / Asha Chotai                   +44 (0)20 3328 5656 
 Peterhouse Capital Limited (Joint Broker) 
  Lucy Williams / Duncan Vasey                   +44 (0)20 7469 0936 
 Stanford Capital Partners Limited (Joint        +44 20 3815 8880 
  Broker) 
  Patrick Claridge / John Howes 
                                                  +44 (0)20 7457 2020 
  Instinctif Partners                             feedbackplc@instinctif.com 
  Rozi Morris/ Deborah Bell/ Phillip Marriage

Notes to editors

About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD(R) , the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). The Company has recently announced the launch of its new messaging and image transfer product Bleepa(TM). For more information, see www.fbk.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

SPMBXGDCISDBGCR

(END) Dow Jones Newswires

September 27, 2019 09:52 ET (13:52 GMT)

Feedback (LSE:FDBK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Feedback.
Feedback (LSE:FDBK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Feedback.